Baird analyst Brian Skorney lowered the firm’s price target on Regeneron (REGN) to $760 from $800 and keeps a Neutral rating on the shares. While Regeneron’s CRL for high-dose aflibercept appears to be a fairly easily addressed manufacturing issue, every day it isn’t on the market is a day Roche’s (RHHBY) Vabysmo gets to build its lead, and it won’t be easy to catch up with a similar profile, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug
- Regeneron downgraded to Hold from Buy at Canaccord
- Regeneron Stock (NASDAQ:REGN) Sinks; FDA Snubs Higher-Dose Eye Drug
- Morgan Stanley says Regeneron likely to come under pressure after surprising CRL
- Regeneron resumes, down 9% after CRL issued for aflibercept 8 mg BLA